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To assess the association between vitamin D defi ciency 
and tuberculosis disease progression, we studied vitamin D 
levels in a cohort of tuberculosis patients and their contacts 
(N = 129) in Pakistan. Most (79%) persons showed defi -
ciency. Low vitamin D levels were associated with a 5-fold 
increased risk for progression to tuberculosis.
Defi ciency of vitamin D (25-hydroxycholecalciferol) has long been implicated in activation of tuberculosis 
(TB) (1). Serum levels of vitamin D in TB patients are low-
er than in healthy controls (2,3). Paradoxically, prolonged 
treatment of TB also causes a decline in serum vitamin D 
levels (2). Several studies have suggested that vitamin D 
is a potent immunomodulator of innate immune responses 
(4,5) by acting as a cofactor for induction of antimycobac-
terial activity (6). Of the 22 countries that have the highest 
TB incidence, Pakistan ranks eighth. In a previous study 
in Karachi, we observed that active disease developed in 7 
(6.4%) of 109 TB case-contacts within 2 years (7). In the 
present study, we explored the role of vitamin D defi ciency 
in TB disease progression within this cohort.
The Study
Household contacts (n = 109) of 20 patients with re-
cently diagnosed sputum-positive pulmonary TB (index 
case-patients) were enrolled at Masoomeen General Hos-
pital, in Karachi during 2001–2004 for a TB household 
cohort study (7). Blood samples were collected at base-
line and at 6, 12, and 24 months follow-up. Visiting health 
workers reviewed clinical charts every 3 months for the 
fi rst 24 months and at a fi nal home study visit during No-
vember 2007–January 2008 (45–74 months from baseline). 
Persons with secondary cases were referred to a consultant 
at Masoomeen General Hospital for additional investiga-
tion, including assessment of physical signs and symptoms, 
laboratory tests, chest radiographs, and sputum smear mi-
croscopy (7). For the present study, 129 de-identifi ed, 
plasma samples preserved at –70°C from the baseline visit 
were shipped to Stanford University (Stanford, CA, USA) 
for analysis of vitamin D levels. Total circulating serum 
25[OH] vitamin D was measured with ELISA by using the 
Immuno Diagnostic System Ltd (IDS, Fountain Hill, AZ, 
USA). All protocols were followed according to manufac-
turer’s instructions. Each test was run in duplicate, with 
mean absorbance computed from the average for 2 wells 
normalized to a zero calibrator well. Levels of vitamin D 
in test samples were derived by fi tting a 2-parameter lo-
gistic curve to 6 standard levels and expressed as ng/mL 
(1 nmol/L × 0.4 = 1 ng/mL). All R2 values were >95%. 
The assay detection range was 6–360 nmol/L (2.4–144 ng/
mL). Levels in 1 person were below the detection limit and 
were excluded from analysis. The ethical review commit-
tees of Aga Khan and Stanford universities approved the 
study protocol.
We used Kaplan-Meier analysis to evaluate the asso-
ciation of vitamin D levels with outcome of TB disease in 
100 household contacts completing >1 follow-up visit. Vi-
tamin D levels in the cohort were classifi ed in population-
based tertiles (low, middle, high). We used SAS version 9.3 
(SAS Institute, Cary, NC, USA) for statistical analyses.
Median vitamin D level for the 128 cohort participants 
was 9.1 ng/mL (interquatrile range [IQR] 5.3–14.7); lev-
els were 9.6 ng/mL (IQR 5.8–19.1) for 100 disease-free 
contacts, 7.9 ng/mL (IQR 4.7–10.3) for 20 TB index case-
patients, 4.6 ng/mL (IQR 4.0–5.2) for 2 co-prevalent TB 
case-patients who were receiving antituberculous treatment 
at recruitment, and 5.1 ng/mL (IQR 3.4–14.3) in 6 house-
hold contacts with a history of TB treatment (2–10 years) 
(Figure 1, panel A). In the 100 disease-free household con-
tacts, vitamin D levels were signifi cantly higher than in the 
28 participants with a history of TB diagnosis at baseline (p 
= 0.02; Mann-Whitney U test) (Figure 1, panel B). Median 
vitamin D levels were signifi cantly lower in the 74 female 
patients than in the 54 male patients (7.8 vs. 11.9, Mann-
Whitney U test, p = 0.0004) (Figure 1, panel C). When we 
stratifi ed the cohort by vitamin D level, 79% had defi cient 
(<20 ng/mL), 14% had insuffi cient (20–30 ng/mL), and 7% 
had suffi cient (>30 ng/mL) levels of vitamin D (Table).
We next analyzed risk for progression to active TB in 
relation to plasma vitamin D levels. Of the 100 disease-free 
household contacts, 8 (8%) progressed to active disease 
during 4 years of follow-up. TB progression was signifi -
cantly associated with relatively lower plasma vitamin D 
levels (Figure 2). Disease progressed in 7 (23%) of 30 pa-
tients with plasma vitamin D levels in the lowest tertile (<7 
ng/mL), 1 (3%) of 32 with vitamin D levels in the middle 
tertile (7–13 ng/mL), and none of 30 in the highest tertile 
(>13 ng/mL) (p = 0.002, log rank). Six (75%) of 8 patients 
whose TB progressed were female patients with vitamin D 
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levels in the lowest tertile. Further adjustment for age and 
sex yielded a relative risk for progression of 5.1 (1.2–21.3, 
p = 0.03) for a relative 1-log decrement in vitamin D levels, 
which suggests that vitamin D defi ciency might be a strong 
risk factor for TB disease.
Conclusion
In this cohort follow-up study from Pakistan, low vita-
min D levels were associated with progression to active TB 
disease in healthy household contacts. No deaths occurred 
during the follow-up period from either TB or unrelated 
causes. Our fi ndings also suggest that vitamin D defi ciency 
may explain the higher susceptibility of women to disease 
progression in our cohort. A high prevalence of vitamin D 
defi ciency in female patients also was reported in ambu-
latory patients at Aga Khan University (8). Factors such 
as low socioeconomic status, poor nutrition, traditional/
cultural traits, and little exposure to sunlight may further 
explain vitamin D defi ciency in female patients in this co-
hort. Despite several limitations to our study, such as infor-
mation about diet, body mass index, exposure to sunlight 
and the relatively small number of study participants, our 
results are supported by a meta-analysis of 7 case-control 
studies in different ethnic populations (including an Indi-
an population) that showed 70% of healthy controls had 
higher vitamin D levels than did untreated TB patients (3). 
Previously in African immigrants in Melbourne, Victoria, 
Australia (9), lower mean vitamin D levels were associated 
with high probability of latent, current, or past TB infection. 
Cross-sectional studies are needed in Pakistan to appreci-
ate this association with sex and susceptibility to TB with 
larger sample size. Most of the South Asian population, 
including Pakistani immigrants to European countries and 
South Indians, had <10 ng/mL of serum vitamin D level 
(10) and is consistent with reports from Aga Khan Hospital 
(8,11). Vitamin D plays an important role in activation of 
1 α-hydroxylase to convert 25(OH) D to its active form [1, 
25 (OH) 2D] that leads to expression of cathelicidin, a mi-
crobicidal peptide for Mycobacterium tuberculosis (5,12). 
Serum levels >30 ng/mL provide an adequate substrate for 
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Figure 1. Levels of vitamin D in plasma in the Karachi, Pakistan, tuberculosis (TB) household cohort (7) by TB status at baseline (disease-
free, index TB case-patient, coprevalent TB case-patient, and past TB case-patient, treated 2–10 years previously). One disease-free 
contact was excluded because of an indeterminate test result. Box plots show the median, 25th, and 75th quartiles of serum vitamin D 
estimated for each group (A) by any TB diagnosis (current or past) at baseline (B) and by sex (C). Reference lines represent cut-offs for 
insuffi cient and suffi cient vitamin D levels, respectively. The Mann-Whitney U test was used for comparison of medians. 
Table. Prevalence of vitamin D deficiency in a cohort study of household contacts of tuberculosis patients, Karachi, Pakistan* 
Baseline characteristic Total, no. (%) Deficient, no. (%) Insufficient, no. (%) Sufficient, no. (%) p value
Age group, y
 6–17 44 (34) 38 (86) 4 (9) 2 (5) 0.13
 >18 84 (66) 63 (75) 14 (17) 7 (8) 
Sex
 Male 54 (42) 35 (65) 12 (22) 7 (13) 0.003 
 Female 74 (58) 66 (89) 6 (8) 2 (3) 
Tuberculin skin test 
 >10 mm 101 (79) 81 (80) 14 (14) 6 (6) 0.49
 <10 mm 27 (21) 20 (74) 4 (15) 3 (11) 
Total 128 (100)† 101 (79) 18 (14) 9 (7) 
*Deficient, <20 ng/mL; insufficient, 20–30 ng/mL; sufficient, >30 ng/mL. p values derived by Ȥ2 test for comparison of deficient and insufficient or sufficient 
levels. 
†Excluding 1 person with indeterminate result. 
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the enzyme. Serum levels <20 ng/mL may therefore impair 
the macrophage-initiated innate immune response to M. tu-
berculosis and offer a possible explanation for geographic 
and ethnic (13) variations in susceptibility to TB.
Vitamin D supplementation during TB treatment re-
mains controversial; a few studies have reported clinical 
improvement in pulmonary TB (14) and 1 study reported 
no effect (15). However, our fi ndings indicate that further 
studies should be conducted regarding use of vitamin D as 
a supplement for persons undergoing treatment for TB and 
those with latent TB infection.
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Figure 2. Risk for tuberculosis (TB) progression, by baseline plasma 
vitamin D level. Risk for progression in 100 household contacts of 
TB patients are indicated in cohort-based tertiles of vitamin D levels 
in plasma at baseline: lowest, <7.4 ng/mL (red); middle, 7.4–13 ng/
mL (black); highest, >13 ng/mL (blue). Plus signs indicate censoring 
points. Events are defi ned as time to diagnosis of active TB disease 
during follow-up.
